Anti-PD-1 (Nivolumab), Humanized Antibody

Monoclonal human IgG1 antibody against human PD-1
Part #: A1307

Availability: In stock

$295.00

Product Details

Cat # +Size A1307-100
Size 100 µg
Antibody Target PD-1
Alternate Name Opdivo, PD-1
Host Human
Antibody Type Monoclonal
Isotype Human IgG4
Immunogen Human programmed cell death 1 receptor (PD1)
Accession # Q02242
Gene ID 18566
Appearance Colorless liquid
Formulation In phosphate buffered saline, pH 7.6
Purification Affinity purified
Species Reactivity Human
Application Neutralization, ELISA
Application & Usage Neutralization: 0.1-1 μg/ml, ELISA: 1 μg/ml
Handling The antibody solution should be gently mixed before use
Storage Conditions -20°C
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.

Details

Nivolumab, trade name Opdivo, is a medication used to treat cancer. It is used as a first line treatment for inoperable or metastatic melanoma in combination with ipilimumab if the cancer does not have a mutation in BRAF, as a second-line treatment following treatment with ipilimumab and if the cancer has a mutation in BRAF, with a BRAF inhibitor, as a second-line treatment for squamous non-small cell lung cancer, and as a second-line treatment for renal cell carcinoma.
$
Subscribe to our Newsletter!!
and automatically get enrolled into a raffle to win Google Home.
Offer valid for US customers only.